Featuring perspectives from Dr Julia Foldi, Dr Laura Huppert, Dr Rita Nanda, Dr Saba Shaikh and Dr Sara M Tolaney, including the following topics:

Introduction: Overview of metastatic triple-negative breast cancer (mTNBC) 

• Current and emerging strategies for patients with mTNBC (0:00)

First-line treatment of mTNBC — Chemotherapy with or without immunotherapy 

• Case: A woman in her early 60s with a history of well-controlled HIV is diagnosed with mTNBC — Dr Shaikh (6:10)
• Case: A woman in her mid 40s with de novo mTNBC — Dr Huppert (20:41)
• Case: A woman in her late 50s with mTNBC receives up-front pembrolizumab/chemotherapy — Dr Foldi (42:15)

Antibody-drug conjugates (ADCs) in the management of mTNBC 

• ADCs in the management of mTNBC; sequencing of these agents and ongoing investigations (51:45)
• Case: A woman in her early 50s with mTNBC receives first-line chemotherapy/immune checkpoint inhibitor followed by sacituzumab govitecan — Dr Shaikh (1:05:32)
• Case: A woman in her late 30s with mTNBC receives sacituzumab govitecan — Dr Huppert (1:14:21)
• Case: A woman in her early 40s with mTNBC (IHC 1+) with sacituzumab govitecan-intolerant disease experiences an excellent response to trastuzumab deruxtecan (T-DXd) — Dr Foldi (1:27:30)
• Case: A woman in her mid 50s with HER2-low metastatic breast cancer receives T-DXd — Dr Shaikh (1:42:00)

PARP inhibition for the treatment of mTNBC 

• Efficacy and tolerability of olaparib in patients with a germline BRCA mutation and HER2-negative breast cancer  (1:49:49)
• Case: A woman in her mid 30s with mTNBC receives olaparib — Dr Foldi (1:54:28)
• Case: A woman in her mid 60s with mTNBC and a BRCA mutation receives olaparib — Dr Huppert (1:59:11)
• Case: A woman in her mid 40s with a BRCA1 germline mutation and mTNBC receives olaparib — Dr Shaikh (2:03:45)

CME information and select publications

Featuring perspectives from Dr Matthew D Galsky, including the following topics:

• HER2 alterations in urothelial cancer and current targeting approaches (0:00)
• Key findings supporting the use of trastuzumab deruxtecan for patients with HER2-overexpressing cancers as part of the Phase II DESTINY-PanTumor02 study (9:39)
• Targeting of HER2 using disitamab vedotin both as a monotherapy and in combination with other treatments (14:31)
• Case: A man in his late 70s with a history of non-muscle-invasive bladder cancer who develops HER2-positive lung metastases (28:57)
• Case: A man in his late 60s who receives disitamab vedotin for HER2 IHC 2+ metastatic urothelial cancer (36:25)
• Enfortumab vedotin and pembrolizumab as first-line or neoadjuvant therapy for targeting HER2-expressing cancers (39:34)
• Future direction of HER2-targeting therapies for urothelial bladder cancer (1:02:48)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Sunnie Kim, including the following topics:

• Year in Review: Novel Treatments and Strategies in Gastroesophageal Cancer — Dr Kim (0:00)
• Case: A man in his mid 50s with poorly differentiated mismatch repair-deficient advanced gastric cancer receives first-line nivolumab/ipilimumab (49:22)
• Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma who experienced disease progression on FOLFOX/trastuzumab receives trastuzumab deruxtecan (54:48)
• Case: A man in his mid 60s with Stage IV, PD-L1-positive GEJ adenocarcinoma (58:11)
• Case: A man in his early 40s with metastatic CLDN18.2-positive gastric/GEJ adenocarcinoma receives zolbetuximab (1:01:10)

CME information and select publications

Featuring perspectives from Prof Eric Van Cutsem, including the following topics:

Immune Checkpoint Inhibitors in Localized Gastroesophageal (GE) Cancers 

• Introduction (0:00)
• Case: A man in his mid 50s with localized, poorly differentiated signet ring, mismatch repair-deficient advanced gastric adenocarcinoma — Sunnie Kim, MD (3:39)

HER2-Positive GE Cancers

• Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma and disease progression on FOLFOX/trastuzumab (PD-L1 CPS 0) — Dr Kim (19:22)

First-Line Treatment of Metastatic Gastric and GEJ Adenocarcinoma

• Case: A man in his early 40s who presents with metastatic GEJ adenocarcinoma (CLDN18.2-positive, PD-L1 CPS 2) in visceral crisis from lung metastases — Dr Kim (38:53)
• Case: A man in his mid 60s with metastatic GEJ adenocarcinoma (PD-L1 CPS 20) — Dr Kim (50:50)

CME information and select publications

Featuring perspectives from Dr Ruben A Mesa, including the following topics:

• Introduction: Journal Club with Dr Mesa (0:00)
• Case: A woman in her mid 80s with an interesting and unusual presentation of primary myelofibrosis — Bhavana (Tina) Bhatnagar, DO (25:33)
• Case: A man in his early 70s, asymptomatic, with lower-risk primary MF (JAK2 V617F mutation) — Susannah Friemel, MD (29:42)
• Case: A woman in her early 80s with pancytopenia and palpable spleen who is diagnosed with primary MF — Jeanne Palmer, MD (35:08)
• Case: A man in his early 70s with multiple comorbidities and MF (CALR mutation) who receives ruxolitinib 10 mg BID — Ranju Gupta, MD (42:40)
• ASH 2023 Review (46:13)
• Faculty Survey (55:41)

CME information and select publications

Featuring perspectives from Prof Nicoletta Colombo, Dr Matthew A Powell and Dr Brian M Slomovitz, moderated by Dr Shannon N Westin, including the following topics:

• Introduction (0:00)
• Current Approaches to First-Line Therapy for Advanced Endometrial Cancer (EC) — Prof Colombo (1:57)
• Novel Investigational Strategies for Newly Diagnosed EC — Dr Westin (25:35)
• Current Options for Relapsed/Refractory EC — Dr Slomovitz (45:57)
• Role of HER2-Targeted Therapy in the Management of Advanced EC — Dr Powell (1:05:54)

CME information and select publications

Featuring perspectives from Dr Carlos M de Castro III, Prof Alexander Röth and Dr Ilene Ceil Weitz, including the following topics:

• Introduction: A Paroxysmal Nocturnal Hemoglobinuria (PNH) Audio Primer for General Medical Oncologists (0:00)
• Biology and Current Clinical Management of PNH (36:35)
• Future Directions in PNH Management (55:34)
• Tolerability and Other Practical Considerations with Available and Emerging Treatments for PNH (1:14:26)

CME information and select publications

Featuring an interview with Dr Emmanuel S Antonarakis, including the following topics:

• Perspectives on advances in the management of prostate cancer over the last decade (0:00)
• Nonmetastatic high-risk prostate cancer and androgen deprivation therapy (ADT) intensification with abiraterone: Insights from the STAMPEDE trial (7:39)
• EMBARK: A Phase III trial of enzalutamide or placebo with leuprolide acetate and enzalutamide monotherapy for high-risk biochemically recurrent prostate cancer (15:25)
• Quality of life and preservation of sexual function with enzalutamide monotherapy compared to ADT alone or enzalutamide with ADT (20:20)
• Management of locally advanced prostate cancer with and without biochemical recurrence (23:58)
• PRESTO trial of ADT intensification with apalutamide with or without abiraterone for high-risk biochemically relapsed prostate cancer (30:35)
• CDK4/6 inhibitors, proteolysis-targeting chimeras and other novel therapeutic approaches for targeting androgen receptor signaling in prostate cancer (31:41)
• Choice of endocrine partner with ADT and incorporation of docetaxel in the treatment of metastatic hormone-sensitive prostate cancer (35:38)
• Other potential novel therapeutic strategies for prostate cancer (42:28)
• Integration of genomic testing for patients with prostate cancer; PARP inhibitor combinations for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (43:57)
• Incorporation of radiopharmaceuticals (ie, lutetium Lu 177 vipivotide tetraxetan, radium-223) into the management of prostate cancer (52:49)
• Perspectives on the results of the Phase III CONTACT-02 trial evaluating cabozantinib in combination with atezolizumab for mCRPC (57:44)

CME information and select publications

Featuring perspectives from Dr Naveen Pemmaraju, including the following topics:

• Recent developments in management approaches for myelofibrosis prior to ASH 2023 (0:00)
• Updated data with navitoclax in combination with ruxolitinib for patients with myelofibrosis (12:35)
• Key findings with pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve myelofibrosis in the Phase III MANIFEST-2 study (22:21)
• Long-term follow-up from the Phase I/III XPORT-MF-034 trial of selinexor with ruxolitinib for JAK inhibitor-naïve myelofibrosis (29:10)
• Effect of new or worsening anemia on clinical outcomes in patients with myelofibrosis treated with ruxolitinib in the expanded-access JUMP study (34:33)
• Results from the Phase III FREEDOM-2 study of fedratinib for patients with myelofibrosis after prior ruxolitinib (40:38)
• Landmark survival analysis of the Phase III PERSIST-2 trial evaluating pacritinib versus best available therapy in patients with myelofibrosis and thrombocytopenia (43:08)
• Retrospective analysis of the PAC203 and PERSIST-2 studies of pacritinib for cytopenic myelofibrosis (47:56)
• Longitudinal assessment of transfusion intensity in patients who received momelotinib for myelofibrosis in the Phase III SIMPLIFY-1 and MOMENTUM trials (52:48)
• Two-year follow-up from the Phase II REVIVE study of rusfertide in phlebotomy-dependent patients with polycythemia vera (55:18)
• Available Phase I/II data with the novel agent zilurgisertib with or without ruxolitinib in patients with anemia due to myelofibrosis (58:56)

CME information and select publications

Featuring perspectives from Dr Andrew H Ko and Dr Eileen M O’Reilly, including the following topics.

• Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Adenocarcinoma (PAD) — Dr Ko (0:00)
• Biomarker-Based Strategies for Metastatic PAD; Novel Investigational Approaches — Dr O’Reilly (31:46)

CME information and select publications

Featuring perspectives from Dr Kristen K Ciombor and Dr John Strickler, including the following topics.

• Select Biomarker-Directed Approaches for Colorectal Cancer (CRC) — Dr Ciombor (0:00)
• HER2-Targeted Approaches for Metastatic CRC (mCRC); Other Available and Emerging Therapeutic Strategies — Dr Strickler (25:17)

CME information and select publications